- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Minnesota Governor Signs Emergency Insulin Bill
A bill designed to provide assistance to patients who cannot afford their insulin was signed into law by Minnesota Governor Tim Walz.
Minnesota Governor Tim Walz, on Thursday, signed into law a bill for emergency insulin, a drug whose high prices are blamed on the difficulty of market entry for rival producers.
The new law requires manufacturers to make at least a 30-day supply of insulin available for those who are in extreme need and have a prescription but cannot afford the drug. Dispensing pharmacies will be to collect a $35 copayment for this 30-day supply from patients with diabetes. Confirmed Minnesota residents may receive up to a 90-day supply. The law provides for hefty fines on manufacturers who do not comply.
State actions to improve access to insulin have come as a newly enacted, abbreviated FDA approval pathway for insulin biosimilars has yet to bear fruit.
The Minnesota action is the latest in a series of moves to address the large number of patients believed to have difficulty coming up with the money needed for diabetes treatment. In March, Medicare announced a test program that would limit the monthly copay for most insulins to $35.
Colorado, Virginia, Maine, and New Mexico have established copay caps ranging from $100 to $25. Other states have enacted similar measures.
PhRMA, a trade group representing pharmaceutical manufacturers, has advocated that rebates and discounts offered within the drug supply chain be reallocated to address insulin affordability issues.
“We also need to advance policy solutions that delink supply chain payments from the list price of a medicine, provide first dollar coverage of insulin for high-deductible health plan patients, count third-party discount programs toward deductibles, and provide flat copays for insulin for patients receiving cost-sharing subsidies in the exchanges,” PhRMA states on its website.
"Not So Different": How the BPCIA Transition Will Affect Biosimilar Uptake
April 10th 2020This week on the podcast, we’re speaking with the executive director of the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC), Cate Lockhart, PharmD, PhD, about the acceptance process for biosimilars in the United States, what BBCIC is doing to help the market develop, and how the new approval pathway for biologics will affect the pace at which biosimilars come to market.
Biosimilars Fuel Price Cuts in European Insulin Glargine Markets
February 14th 2025Although Lantus continues to lead the insulin glargine market globally, the rise of biosimilars like Abasaglar and Semglee has sparked significant price reductions, with some European countries seeing discounts of up to 42.3%.
Aflibercept Biosimilar MYL-1701P Provides Equivalence in DME Therapy
November 27th 2024The study findings demonstrate that the aflibercept biosimilar MYL-1701P is as effective and safe as the reference aflibercept in treating diabetic macular edema (DME), offering a promising option for reducing treatment costs and improving global access to care for patients with DME.
Samsung Bioepis Report Showcases Adalimumab Biosimilar Growth in Market Share
October 11th 2024Adalimumab biosimilars have seen a significant increase in market share, from 2% in early 2024 to 22%, as payers and pharmacy benefit managers begin to prioritize these biosimilars over the reference product, Humira.
